ES2103966T3 - Uso de una timosina en el tratamiento de hepatitis c. - Google Patents

Uso de una timosina en el tratamiento de hepatitis c.

Info

Publication number
ES2103966T3
ES2103966T3 ES92919977T ES92919977T ES2103966T3 ES 2103966 T3 ES2103966 T3 ES 2103966T3 ES 92919977 T ES92919977 T ES 92919977T ES 92919977 T ES92919977 T ES 92919977T ES 2103966 T3 ES2103966 T3 ES 2103966T3
Authority
ES
Spain
Prior art keywords
treatment
hepatitis
thymosine
thymosines
alone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92919977T
Other languages
English (en)
Spanish (es)
Inventor
Milton Mutchnick
Paul Chretian
Kenneth E Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Alpha 1 Biomedicals Inc
United States Department of the Army
Original Assignee
Wayne State University
Alpha 1 Biomedicals Inc
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Alpha 1 Biomedicals Inc, United States Department of the Army filed Critical Wayne State University
Application granted granted Critical
Publication of ES2103966T3 publication Critical patent/ES2103966T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
ES92919977T 1991-09-13 1992-09-08 Uso de una timosina en el tratamiento de hepatitis c. Expired - Lifetime ES2103966T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13

Publications (1)

Publication Number Publication Date
ES2103966T3 true ES2103966T3 (es) 1997-10-01

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92919977T Expired - Lifetime ES2103966T3 (es) 1991-09-13 1992-09-08 Uso de una timosina en el tratamiento de hepatitis c.

Country Status (23)

Country Link
US (3) US6001799A (enExample)
EP (1) EP0603305B1 (enExample)
JP (1) JP3228512B2 (enExample)
KR (1) KR100254082B1 (enExample)
AT (1) ATE152914T1 (enExample)
AU (1) AU667327B2 (enExample)
CA (1) CA2119006C (enExample)
CZ (1) CZ286827B6 (enExample)
DE (1) DE69219782T2 (enExample)
DK (1) DK0603305T3 (enExample)
ES (1) ES2103966T3 (enExample)
FI (1) FI107879B (enExample)
GR (1) GR3024025T3 (enExample)
HK (1) HK1021687A1 (enExample)
HU (1) HU221006B1 (enExample)
MX (1) MX9205240A (enExample)
NO (1) NO941310D0 (enExample)
RO (1) RO111991B1 (enExample)
RU (1) RU2104010C1 (enExample)
SG (1) SG64897A1 (enExample)
TW (1) TW224053B (enExample)
WO (1) WO1993005806A1 (enExample)
ZA (1) ZA926964B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132037A1 (es) * 2006-05-10 2007-11-22 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien
EP0728010A4 (en) * 1992-02-06 1997-10-01 Sciclone Pharmaceuticals METHOD FOR TREATING HEPATITIS B CARRIERS WITH A MINOR DISEASE
AU4671193A (en) * 1992-07-13 1994-01-31 Kenneth E. Sherman Composition and method of treating hepatitis b
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
ES2194860T3 (es) * 1993-11-05 2003-12-01 Sciclone Pharmaceuticals Inc Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
GEP20012489B (en) * 1996-02-28 2001-07-25 Ifi Inst Farmacoterapico Italiano S P A Use of Natural Human α-Interferon
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
AU8353601A (en) * 2000-08-07 2002-02-18 Sciclone Pharmaceuticals Inc Treatment of hepatitis c with thymosin, interferon and ribavirin
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
CN1564693A (zh) * 2001-10-05 2005-01-12 印特缪恩股份有限公司 治疗肝纤维化和丙型肝炎病毒感染的方法
WO2003035010A2 (en) * 2001-10-26 2003-05-01 Rhode Island Hospital Thymosin augmentation of genetic immunization
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
EP1480982A4 (en) * 2002-02-14 2007-08-01 Pharmasset Inc MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
AU2003247084B9 (en) 2002-06-28 2018-07-26 Centre National De La Recherche Scientifique Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
PT1613340E (pt) * 2003-03-28 2010-08-19 Sciclone Pharmaceuticals Inc Tratamento de infecções por aspergillus com timosina alfa 1
JP4629033B2 (ja) 2003-03-28 2011-02-09 サイクローン・ファーマシューティカルズ・インコーポレイテッド チモシンα１によるアスペルギルス感染の治療
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
RU2358979C2 (ru) 2003-05-30 2009-06-20 Фармассет, Инк. Модифицированные фторированные аналоги нуклеозида
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
ES2725457T3 (es) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US7781576B2 (en) 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
JP5441685B2 (ja) * 2006-05-02 2014-03-12 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ チモシンα１の、単独またはＰＴＸ３またはガンシクロビルとの組合せにおける、サイトメガロウイルス感染の処置のための使用
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20110195048A1 (en) * 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132037A1 (es) * 2006-05-10 2007-11-22 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas
ES2288118A1 (es) * 2006-05-10 2007-12-16 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.

Also Published As

Publication number Publication date
FI941133A0 (fi) 1994-03-10
HU9400758D0 (en) 1994-06-28
HU221006B1 (hu) 2002-07-29
EP0603305B1 (en) 1997-05-14
JP3228512B2 (ja) 2001-11-12
RU94022480A (ru) 1996-07-20
US5849696A (en) 1998-12-15
MX9205240A (es) 1993-07-01
JPH06510998A (ja) 1994-12-08
FI107879B (fi) 2001-10-31
AU2644792A (en) 1993-04-27
TW224053B (enExample) 1994-05-21
NO941310L (no) 1994-04-12
DK0603305T3 (da) 1997-09-01
DE69219782D1 (de) 1997-06-19
SG64897A1 (en) 1999-05-25
CZ286827B6 (cs) 2000-07-12
WO1993005806A1 (en) 1993-04-01
US20070218033A1 (en) 2007-09-20
DE69219782T2 (de) 1997-10-09
ATE152914T1 (de) 1997-05-15
CZ55194A3 (en) 1994-10-19
HK1021687A1 (en) 2000-06-23
AU667327B2 (en) 1996-03-21
CA2119006A1 (en) 1993-04-01
HUT75166A (en) 1997-04-28
RO111991B1 (ro) 1997-04-30
RU2104010C1 (ru) 1998-02-10
CA2119006C (en) 2005-08-23
US6001799A (en) 1999-12-14
GR3024025T3 (en) 1997-10-31
NO941310D0 (no) 1994-04-12
ZA926964B (en) 1993-04-26
EP0603305A1 (en) 1994-06-29
FI941133L (fi) 1994-03-10
KR100254082B1 (ko) 2000-09-01

Similar Documents

Publication Publication Date Title
MX9205240A (es) Composicion y metodo para tratar hepatitis c.
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
NO994091L (no) Medisinsk preparat inneholdende en lipofilisk inertgass
ES2188583T3 (es) Polipeptidos para el virus de la hepatitis c (hcv).
ES2143558T3 (es) Agentes policiclicos antiparasitarios, procedimiento y cepa para su preparacion y su uso.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
ES2182837T3 (es) Piran-2-onas y 5,6-dihidropiran-2-onas utiles en el tratamiento del sida y de otros retrovirus.
MX17808A (es) Nuevos derivados de artemisinina,procedimiento para su preparacion y su uso como agentes antiprosoos
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ES2105684T3 (es) Derivados insaturados de fosfonato de purinas y pirimidinas.
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
MX9304209A (es) Composicion y metodo de tratamiento de hepatitis b.
ES2100689T3 (es) Asociacion sinergizante que tiene un efecto antagonista de los receptores nk1 y nk2.
ES2120962T3 (es) Composicion antivirica.
NO890046L (no) Disubstituerte pyridiner.
TR199801289T2 (en) Terap�tik bile�ikler.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
ITMI912509A1 (it) Uso della nimesulide nel trattamento della cataratta
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
FI892222A0 (fi) Peptidalkoholer med antikoagulantverkan.
ES2036526T3 (es) Composiciones de interferon.
ATE71840T1 (de) Virushemmende nukleosidmischung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 603305

Country of ref document: ES